Table 2. Evaluation of prognostic role of tumoral CD105 on OS and DFS in univariate and multivariate analyses.
| |
Crude estimates |
Adjusted estimates | ||||
|---|---|---|---|---|---|---|
| HR | (95% CI) | P-value | HR | (95% CI) | P-value | |
|
OS in all cohort (Patients
n=102) | ||||||
| Age | 1.01 | 0.98–1.04 | 0.71 | |||
| Sex (M/F) | 1.72 | 0.70–4.24 | 0.24 | |||
| Stage (M1/M0) | 3.81 | 1.71–8.45 | 0.001 | 2.27 | 0.95–5.42 | 0.066 |
| Tumoral CD105 (Positive/negative) |
4.82 |
2.23–4.82 |
<0.001 |
3.76 |
1.63–8.66 |
0.002* |
|
DFS (Patients
n=87) | ||||||
| Age | 1.02 | 0.98–1.05 | 0.44 | |||
| Sex (M/F) | 2.73 | 0.79–9.46 | 0.11 | |||
| Leibovich risk groups (Low/intermediate/high) | 4.23 | 2.19–8.17 | <0.001 | 3.21 | 1.54–6.66 | 0.002* |
| Tumoral CD105 (Positive/negative) | 7.37 | 2.88–18.9 | <0.001 | 2.82 | 0.99–8.05 | 0.053 |
Abbreviations: CD105=cluster of differentiation molecule 105; CI=confidence interval; DFS=disease-free survival; F=female; HR=hazard ratio; M=male; M0=non-metastatic group; M1=metastatic group; OS=overall survival.
*P<0.05 (statistically significant difference).